Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.

ABSTRACT:

Introduction

Despite a recent increase in US FDA-approved treatments, genitourinary malignancies remain a source of significant morbidity and mortality. One focus of research is the use of therapeutic cancer vaccines in these diseases, and a significant body of clinical trial experience now exists for refining vaccine strategies to enhance antitumor efficacy and develop immune-based combination regimens.

Areas covered

In recent years, clinical data from multiple trials in genitourinary malignancies have enhanced our understanding of the potential for immunotherapy in these cancers. There are also emerging clinical strategies that combine cancer vaccines with chemotherapy, radiation, androgen-deprivation therapy and immune checkpoint inhibitors. This review is based on a sear

SUBMITTER: Surolia I 

PROVIDER: S-EPMC8262094 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature